CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 19-898/S032

PHARMACOLOGY REVIEW(S)
REVIEW AND EVALUATION OF PHARMACOLOGY/TOXICOLOGY DATA:

KEY WORDS:

Reviewer Name: Ronald W. Steigerwalt, Ph.D. Pharmacology Team Leader
Division Name: Division of Metabolic and Endocrine Drug Products (DMEDP)
HFD#510
Review Completion Date: August 6, 1999
Review number: 3 (for this reviewer)

IND/NDA NUMBER: NDA 19-898
Serial number/date/type of submission: S-032/ April 13, 1999
Information to sponsor: Yes () No (X)
Sponsor (or agent): Bristol-Meyers Squibb Pharmaceutical Research Institute; P.O. Box 5400
Princeton, NJ 08534-5400

DRUG
Trade Name: PRAVACHOL®
Chemical Name: 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro-(β),6-trihydroxy-2-
methyl-8-(2-methyl-1-oxobutoxy)-,monosodium salt, [1S-
[1(α)(β)S*,[β]S*)2α,6(α),8(β)(R*),8a(α)]]-

Relevant INDS/NDAs/DMFs: NDA 19-898 approved in 1991

Drug Class: HMG-CoA Reductase inhibitor “statin”

Indication: Cholesterol lowering drug: Primary prevention of coronary events, secondary
prevention of cardiovascular events; reduction of risk of recurrent myocardial infarction.

Clinical formulation: 10, 20, 40 mg tablets with inactive ingredients of croscarmellose sodium,
lactose, magnesium oxide, magnesium stearate, microcrystalline cellulose, and povidone. Each
tablet size also contains approved dyes.

Route of administration: Oral

Proposed clinical protocol or Use: Supplement S–032 Includes new indications follows:
LIPID clinical study data to add indication of decreased risk of total mortality, death due to
chronic heart disease; risk of stroke and transient ischemic attacks and reduce total
hospitalization.

SUMMARY:
PRAVACHOL® is an HMG-CoA Reductase inhibitor that was approved in 1991 at the doses
indicated in this supplement. This supplement contained only clinical or clinical pharmacology
modifications. There were no preclinical studies submitted with thus supplement. No nonclinical
data were necessary to support the proposed changes. No further review from pharmacology is
necessary. There is an additional, separate supplement which addresses preclinical labeling
issues and labeling will be considered under the appropriate supplement.
RECOMMENDATIONS:

From a pharmacology standpoint, the supplement 032 may be approved.

APPEARS THIS WAY ON ORIGINAL

cc: IND Arch
    HFD510
    HFD510/Steigerwalt/Simoneau/
    Review Code: AP
    Filename: 19898.32.doc

/S/
Ronald W. Steigerwalt, Ph.D.
Pharmacology Team Leader
8/6/91

APPEARS THIS WAY ON ORIGINAL